Using psilocybin to investigate the relationship between attention, working memory and the serotonin 5-HT1A and 5-HT2A receptors
Olivia Carter, David C. Burr, John D. Pettigrew, Franz X. Vollenweider
Journal of Vision March 17, 2010 DOI: 10.1167/5.8.683 via OpenAlex
Summary
AI-generated from the abstractA hallucinogenic drug that activates serotonin receptors, psilocybin, impairs the ability to track multiple moving objects but does not affect spatial working memory, indicating a functional separation between these two cognitive processes. Blocking one type of serotonin receptor (5-HT2A) with ketanserin did not prevent this attentional deficit, pointing to the involvement of another receptor (5-HT1A) instead. The impairment may stem from difficulty ignoring distractions rather than a reduction in attentional capacity itself.
Study at a glance
| Characteristics | Within-subjects pharmacological challenge Peer reviewed |
|---|---|
| Sample size | 8 |
| Population | Healthy human volunteers |
| Interventions | Psilocybin Ketanserin |
| Topics | Psilocybin Serotonin |
| Keywords | Ketanserin Working memory Prefrontal cortex Agonist |
| Citations | 6 |
| Key finding | Psilocybin significantly reduced attentional tracking ability but had no significant effect on spatial working memory, and ketanserin pretreatment did not attenuate this attentional deficit. |
Abstract
Increasing evidence suggests a link between attention, working memory, serotonin (5-HT) and prefrontal cortex activity. In an attempt to tease out the relationship between these elements, this study tested the effects of the hallucinogenic 5-HT1A/2A receptor agonist psilocybin alone and after pretreatment with the 5-HT2A antagonist ketanserin on multiple object tracking and spatial working memory, in eight healthy human volunteers. Psilocybin significantly reduced attentional tracking ability, but had no significant effect on spatial working memory, suggesting a functional dissociation between the two tasks. In line with the 5-HT1A receptor's known role in modulating prefrontal activity, pretreatment with ketanserin did not attenuate the effect of psilocybin on attentional performance, suggesting a primary involvement of the 5-HT1A receptor in the observed deficit. Based on physiological and pharmacological data, we propose that this impaired attentional performance may reflect reduced ability to suppress or ignore distracting stimuli rather than reduced attentional capacity.